Xeris Biopharma Holdings (XERS) Other Operating Expenses (2020 - 2026)

Xeris Biopharma Holdings has reported Other Operating Expenses for 7 years, with the latest figure at $13.3 million in Q1 2026.

• For the quarter ending Q1 2026, Other Operating Expenses rose 16.14% year-over-year to $13.3 million; the trailing twelve-month figure through Mar 2026 stood at $55.3 million (up 9.57% YoY), and the FY2025 full-year result was $53.4 million, up 12.03% from the prior year.
• Other Operating Expenses for Q1 2026 stood at $13.3 million, down from $13.7 million in the prior quarter.
• The five-year high for Other Operating Expenses was $16.3 million in Q3 2024, with the low at $7.5 million in Q2 2022.
• Historically, Other Operating Expenses has averaged $11.0 million across 5 years, with a median of $10.5 million in 2024.
• Annual changes were most pronounced in 2022 — Other Operating Expenses surged 392.0% — and 2025, when it retreated 15.93%.
• Xeris Biopharma Holdings' Other Operating Expenses stood at $9.0 million in 2022, then increased by 14.21% to $10.3 million in 2023, then increased by 18.56% to $12.2 million in 2024, then rose by 12.05% to $13.7 million in 2025, then declined by 2.74% to $13.3 million in 2026.
• The last three Other Operating Expenses figures came in at $13.3 million (Q1 2026), $13.7 million (Q4 2025), and $13.7 million (Q3 2025), per Business Quant data.